Zeracizumab Is an Experimental Angiogenesis Inhibitor Targeting Vascular Endothelial Growth

question 107

Multiple Choice

Zeracizumab is an experimental angiogenesis inhibitor targeting vascular endothelial growth factor that is being tested for the treatment of advanced, chemotherapy-naive, non-squamous non-small cell lung cancer (NSCLC) .  Part of the drug company's evaluation process is to analyze the 1-year survival after treatment to determine the clinical efficacy of the experimental treatment.  The results are given in the table below. Which of the following best represents the number needed to harm for the zeracizumab-containing regimen?

• A)2
• B)25
• C)40
• D)72
• E)94

---

Definitions:

Indirect Approach

A communication strategy where the main point or request is not presented immediately but is preceded by context, background, or supportive arguments.

Providing Sample

Offering a portion or example of a product or work to demonstrate quality, style, or function.

Reader's Attention

The focus and engagement of a reader with the content, influenced by factors such as interest, readability, and presentation.

Persuasive Claim

An assertion made in an attempt to convince others of its validity, often used in arguments or advertisements.